We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+34.87%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$11.6B
AUM Growth
+$2.27B
(+24%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-2.4%
Top 10 Holdings %
Top 10 Hldgs %
30.23%
Holding
354
New
65
Increased
75
Reduced
125
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$106M |
| 2 |
Meta Platforms (Facebook)
META
|
+$106M |
| 3 |
PayPal
PYPL
|
+$105M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$99.5M |
| 5 |
Ciena
CIEN
|
+$86.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$85.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$84.6M |
| 3 |
Amazon
AMZN
|
+$72.7M |
| 4 |
Intel
INTC
|
+$72.2M |
| 5 |
RingCentral
RNG
|
+$71.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.14% |
| 2 | Healthcare | 19.11% |
| 3 | Financials | 17.15% |
| 4 | Communication Services | 12.94% |
| 5 | Consumer Discretionary | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
DexCom
DXCM
$29B
| $19.9M | 0.17% |
196,072
-1,836
| -0.9% | -$164K |
|
|
TMHC
127
DELISTED
Taylor Morrison
TMHC
| $19.7M | 0.17% |
1,021,601
-128,422
| -11% | -$2.02M |
|
|
SGEN
128
DELISTED
Seagen Inc. Common Stock
SGEN
| $19.5M | 0.17% |
115,000
-85,000
| -43% | -$12.7M |
|
129
eBay
EBAY
$51.2B
| $19.4M | 0.17% |
369,266
-232,397
| -39% | -$9.82M |
|
130
Booking.com
BKNG
$156B
| $18.9M | 0.16% |
296,800
+4,675
| +2% | +$285K |
|
131
MongoDB
MDB
$25.8B
| $17.9M | 0.15% |
+79,240
| New | +$14.7M |
|
132
Gilead Sciences
GILD
$165B
| $17.3M | 0.15% |
+225,000
| New | +$17.2M |
|
133
AtriCure
ATRC
$2.08B
| $17.2M | 0.15% |
+383,125
| New | +$16.7M |
|
134
Becton Dickinson
BDX
$46.4B
| $16.4M | 0.14% |
70,061
-686
| -1% | -$165K |
|
135
Wolfspeed
WOLF
$1.04B
| $15.7M | 0.14% |
+264,775
| New | +$12.7M |
|
136
BlackLine
BL
$1.9B
| $14.9M | 0.13% |
+180,143
| New | +$12M |
|
137
Aflac
AFL
$65.5B
| $14.8M | 0.13% |
410,000
| – | – |
|
|
CHNGU
138
DELISTED
Change Healthcare Inc. Tangible Equity Units
CHNGU
| $14.7M | 0.13% |
335,000
-110,000
| -25% | -$4.9M |
|
|
NSTG
139
DELISTED
NanoString Technologies, Inc.
NSTG
| $14.7M | 0.13% |
500,000
-469,120
| -48% | -$14M |
|
140
Bank of America
BAC
$429B
| $14.6M | 0.13% |
615,084
-242,925
| -28% | -$5.74M |
|
|
SYNH
141
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $14.2M | 0.12% |
+244,410
| New | +$13.1M |
|
142
JPMorgan Chase
JPM
$916B
| $14.2M | 0.12% |
150,741
-72,377
| -32% | -$6.87M |
|
143
Mohawk Industries
MHK
$6.91B
| $13.8M | 0.12% |
135,513
-10,206
| -7% | -$898K |
|
144
Align Technology
ALGN
$12.9B
| $13.6M | 0.12% |
+49,713
| New | +$11.2M |
|
145
Arcutis Biotherapeutics
ARQT
$3.48B
| $13.6M | 0.12% |
450,000
+75,000
| +20% | +$2.17M |
|
146
Summit Therapeutics
SMMT
$10.2B
| $13.4M | 0.12% |
4,500,000
+1,000,000
| +29% | +$3.45M |
|
147
Rockwell Automation
ROK
$51.1B
| $13.3M | 0.11% |
62,278
+22,129
| +55% | +$4.28M |
|
|
148
Bristol-Myers Squibb
BMY
$129B
| $13.1M | 0.11% |
222,406
-1,414,656
| -86% | -$84.6M |
|
149
Pacific Biosciences
PACB
$435M
| $12.9M | 0.11% |
3,750,000
+175,024
| +5% | +$596K |
|
150
Veeco
VECO
$2.62B
| $12.9M | 0.11% |
955,604
+249,322
| +35% | +$2.86M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Polar Capital held 354 positions worth $11.6B, up 24% from $9.31B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Polar Capital's Q2 2020 filing shows 65 new, 75 increased, 125 reduced and 74 closed positions. Its largest new stake was TripAdvisor: 3,886,053 shares worth $73.9M. The largest sale was AbbVie, an estimated $85.6M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 36% a quarter earlier, followed by Healthcare and Financials.
- Polar Capital's largest Q2 2020 buy was TripAdvisor: 3,886,053 shares worth $73.9M.
- Polar Capital added most to UnitedHealth in Q2 2020, an estimated $106M increase.
- Polar Capital's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $84.6M.
- Polar Capital fully exited AbbVie in Q2 2020, selling an estimated $85.6M.
- Polar Capital's ten largest holdings make up 30% of its $11.6B portfolio in Q2 2020.
- Polar Capital opened 65 new positions and closed 74 in Q2 2020.
- Polar Capital's portfolio value rose 24% quarter-over-quarter to $11.6B.
Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.